DE1420015B1
(de)
*
|
1959-10-16 |
1971-08-26 |
Boehringer Sohn Ingelheim |
2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
|
US3854480A
(en)
|
1969-04-01 |
1974-12-17 |
Alza Corp |
Drug-delivery system
|
US3937801A
(en)
*
|
1973-07-10 |
1976-02-10 |
American Home Products Corporation |
Reducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs
|
US4115400A
(en)
|
1976-05-27 |
1978-09-19 |
Eli Lilly And Company |
1-Azoniabicyclo[3.1.0]hexanes
|
US4176186A
(en)
|
1978-07-28 |
1979-11-27 |
Boehringer Ingelheim Gmbh |
Quaternary derivatives of noroxymorphone which relieve intestinal immobility
|
JPS5535031A
(en)
*
|
1978-09-04 |
1980-03-11 |
Shin Etsu Chem Co Ltd |
Enteric coating composition
|
US4311833A
(en)
*
|
1979-03-06 |
1982-01-19 |
Daicel Chemical Industries Ltd. |
Process for preparing ethylcarboxymethylcellulose
|
US4322426A
(en)
*
|
1980-04-28 |
1982-03-30 |
E. I. Du Pont De Nemours And Company |
17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
|
US4675189A
(en)
*
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
US4466968A
(en)
*
|
1980-11-24 |
1984-08-21 |
Dermall, Ltd. |
Method for prophylaxis or treatment of emesis and nausea
|
US4427676A
(en)
*
|
1980-12-19 |
1984-01-24 |
John Wyeth & Brother Ltd. |
Thiomorpholine derivatives
|
US4377568A
(en)
*
|
1981-08-12 |
1983-03-22 |
Merck Sharp & Dohme (I.A.) Corp. |
Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
|
DK150008C
(da)
*
|
1981-11-20 |
1987-05-25 |
Benzon As Alfred |
Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
|
DE3381877D1
(de)
|
1982-03-16 |
1990-10-18 |
Univ Rockefeller |
Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
|
US4987136A
(en)
*
|
1982-03-16 |
1991-01-22 |
The Rockefeller University |
Method for controlling gastrointestinal dysmotility
|
US4457907A
(en)
*
|
1982-08-05 |
1984-07-03 |
Clear Lake Development Group |
Composition and method for protecting a therapeutic drug
|
US4518433A
(en)
*
|
1982-11-08 |
1985-05-21 |
Fmc Corporation |
Enteric coating for pharmaceutical dosage forms
|
US4452775A
(en)
*
|
1982-12-03 |
1984-06-05 |
Syntex (U.S.A.) Inc. |
Cholesterol matrix delivery system for sustained release of macromolecules
|
US4462839A
(en)
*
|
1983-06-16 |
1984-07-31 |
Fmc Corporation |
Enteric coating for pharmaceutical dosage forms
|
US4556552A
(en)
|
1983-09-19 |
1985-12-03 |
Colorcon, Inc. |
Enteric film-coating compositions
|
US4581456A
(en)
*
|
1983-09-21 |
1986-04-08 |
Eli Lilly And Company |
Processes for preparing picenadol precursors and novel intermediates thereof
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
US5266574A
(en)
*
|
1984-04-09 |
1993-11-30 |
Ian S. Zagon |
Growth regulation and related applications of opioid antagonists
|
US4689332A
(en)
*
|
1984-04-09 |
1987-08-25 |
Research Corporation |
Growth regulation and related applications of opioid antagonists
|
JPS6229515A
(ja)
*
|
1985-07-30 |
1987-02-07 |
Shinjiro Tsuji |
硬カプセル剤のフイルムコ−テイング方法
|
US4806556A
(en)
*
|
1985-12-12 |
1989-02-21 |
Regents Of The University Of Minnesota |
Gut-selective opiates
|
US4730048A
(en)
*
|
1985-12-12 |
1988-03-08 |
Regents Of The University Of Minnesota |
Gut-selective opiates
|
US4861781A
(en)
|
1986-03-07 |
1989-08-29 |
The University Of Chicago |
Quaternary derivatives of noroxymorphone which relieve nausea and emesis
|
US4719215A
(en)
*
|
1986-03-07 |
1988-01-12 |
University Of Chicago |
Quaternary derivatives of noroxymorphone which relieve nausea and emesis
|
EP0306575B1
(en)
|
1987-09-10 |
1992-07-29 |
The University Of Chicago |
Quaternary derivatives of noroxymorphone which relieve nausea and emesis
|
DE3609073C2
(de)
*
|
1986-03-18 |
1995-08-10 |
Hans J Prof Dr Rer Nat Schmitt |
Meßeinrichtung zur nichtinvasiven Feststellung peripherer Abfluß- und Durchflußstörungen in menschlichen Extremitäten
|
US4673679A
(en)
|
1986-05-14 |
1987-06-16 |
E. I. Du Pont De Nemours And Company |
Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
|
JP2593501B2
(ja)
|
1986-08-28 |
1997-03-26 |
コーテクス・リミテッド |
動物成長促進剤
|
US5597564A
(en)
*
|
1986-08-28 |
1997-01-28 |
Enzacor Properties Limited |
Method of administering a microgranular preparation to the intestinal region of animals
|
US4888346A
(en)
|
1986-10-07 |
1989-12-19 |
Bernard Bihari |
Method for the treatment of persons infected with HTLV-III (AIDS) virus
|
FR2609632B1
(fr)
|
1987-01-21 |
1991-03-29 |
Shelly Marc |
Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
|
NL8700842A
(es)
|
1987-04-10 |
1988-11-01 |
Duphar Int Res |
|
US4891379A
(en)
*
|
1987-04-16 |
1990-01-02 |
Kabushiki Kaisha Kobe Seikosho |
Piperidine opioid antagonists
|
CA1315689C
(en)
|
1987-09-03 |
1993-04-06 |
Leon I. Goldberg |
Quarternary derivatives of noroxymorphone which relieve nausea and emesis
|
US4912114A
(en)
*
|
1988-03-18 |
1990-03-27 |
Sandoz Ltd. |
Morphinan derivatives
|
EP0352361A1
(en)
|
1988-07-29 |
1990-01-31 |
The Rockefeller University |
Method of treating patients suffering from chronic pain or chronic cough
|
US4857533A
(en)
|
1988-12-15 |
1989-08-15 |
Baker Cummins Pharmaceuticals, Inc. |
Method of treatment for autoimmune diseases
|
US4863928A
(en)
|
1989-01-04 |
1989-09-05 |
Baker Cummins Pharmaceuticals, Inc. |
Method of treatment for arthritic and inflammatory diseases
|
US5102887A
(en)
*
|
1989-02-17 |
1992-04-07 |
Arch Development Corporation |
Method for reducing emesis and nausea induced by the administration of an emesis causing agent
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
US4965269A
(en)
|
1989-12-20 |
1990-10-23 |
Ab Hassle |
Therapeutically active chloro substituted benzimidazoles
|
CA2081564C
(en)
*
|
1990-05-11 |
1998-02-03 |
Anthony Andrea Fossa |
Synergistic therapeutic compositions and methods
|
JPH04230625A
(ja)
*
|
1990-12-27 |
1992-08-19 |
Standard Chem & Pharmaceut Corp Ltd |
噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
|
DE69231274T2
(de)
|
1991-02-25 |
2000-11-30 |
Univ Boston |
Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
|
US5159081A
(en)
|
1991-03-29 |
1992-10-27 |
Eli Lilly And Company |
Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
|
US5270328A
(en)
|
1991-03-29 |
1993-12-14 |
Eli Lilly And Company |
Peripherally selective piperidine opioid antagonists
|
CA2064373C
(en)
|
1991-03-29 |
2005-08-23 |
Buddy Eugene Cantrell |
Piperidine derivatives
|
US5250542A
(en)
|
1991-03-29 |
1993-10-05 |
Eli Lilly And Company |
Peripherally selective piperidine carboxylate opioid antagonists
|
WO1993000077A1
(en)
*
|
1991-06-21 |
1993-01-07 |
University Of Cincinnati |
Orally administrable therapeutic proteins and method of making
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
US5614219A
(en)
|
1991-12-05 |
1997-03-25 |
Alfatec-Pharma Gmbh |
Oral administration form for peptide pharmaceutical substances, in particular insulin
|
US5985880A
(en)
|
1996-06-05 |
1999-11-16 |
Delta Pharmaceuticals |
Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
|
CA2130563C
(en)
|
1992-02-24 |
1997-11-11 |
Maurice W. Gittos |
2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist
|
US5472943A
(en)
|
1992-09-21 |
1995-12-05 |
Albert Einstein College Of Medicine Of Yeshiva University, |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
|
USRE36547E
(en)
*
|
1992-09-21 |
2000-02-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
|
US5512578A
(en)
*
|
1992-09-21 |
1996-04-30 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
|
US5580876A
(en)
|
1992-09-21 |
1996-12-03 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
US6096756A
(en)
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
ES2173873T5
(es)
|
1992-10-28 |
2007-03-01 |
Genentech, Inc. |
Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer.
|
DE69305313T3
(de)
*
|
1992-12-22 |
2001-06-21 |
Univ Cincinnati Cincinnati |
Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen
|
DE4303214A1
(de)
|
1993-02-04 |
1994-08-11 |
Wolfgang Marks |
Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
|
US5656290A
(en)
|
1993-02-26 |
1997-08-12 |
The Procter & Gamble Company |
Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
|
US5391372A
(en)
*
|
1993-06-28 |
1995-02-21 |
Campbell; Elizabeth |
Methods of treating colic and founder in horses
|
GB2281205A
(en)
|
1993-08-24 |
1995-03-01 |
Euro Celtique Sa |
Oral opioid analgesic
|
WO1995009168A1
(fr)
|
1993-09-30 |
1995-04-06 |
Tokyo Tanabe Company Limited |
Compose d'indoline et antagoniste des recepteurs de 5-ht3 contenant ce compose comme principe actif
|
US5434171A
(en)
*
|
1993-12-08 |
1995-07-18 |
Eli Lilly And Company |
Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
|
EP0758403B1
(en)
|
1994-05-05 |
1998-06-24 |
Beckman Instruments, Inc. |
Oligonucleotide repeat arrays
|
IT1269826B
(it)
|
1994-05-24 |
1997-04-15 |
Paolo Minoia |
Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
|
US5536507A
(en)
*
|
1994-06-24 |
1996-07-16 |
Bristol-Myers Squibb Company |
Colonic drug delivery system
|
US5866154A
(en)
|
1994-10-07 |
1999-02-02 |
The Dupont Merck Pharmaceutical Company |
Stabilized naloxone formulations
|
US5614222A
(en)
|
1994-10-25 |
1997-03-25 |
Kaplan; Milton R. |
Stable aqueous drug suspensions and methods for preparation thereof
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
ES2094694B1
(es)
|
1995-02-01 |
1997-12-16 |
Esteve Quimica Sa |
Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
|
US6096763A
(en)
|
1995-02-23 |
2000-08-01 |
Merck & Co., Inc. |
α1a adrenergic receptor antagonists
|
US6025154A
(en)
|
1995-06-06 |
2000-02-15 |
Human Genome Sciences, Inc. |
Polynucleotides encoding human G-protein chemokine receptor HDGNR10
|
US5821219A
(en)
|
1995-08-11 |
1998-10-13 |
Oregon Health Sciences University |
Opioid antagonists and methods of their use
|
US5736152A
(en)
*
|
1995-10-27 |
1998-04-07 |
Atrix Laboratories, Inc. |
Non-polymeric sustained release delivery system
|
US5804595A
(en)
|
1995-12-05 |
1998-09-08 |
Regents Of The University Of Minnesota |
Kappa opioid receptor agonists
|
PT914097E
(pt)
|
1996-03-12 |
2002-06-28 |
Alza Corp |
Composicao e forma de dosagem compreendendo antagonista de opioide
|
US6136780A
(en)
|
1996-03-29 |
2000-10-24 |
The Penn State Research Foundation |
Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
|
US20040024006A1
(en)
*
|
1996-05-06 |
2004-02-05 |
Simon David Lew |
Opioid pharmaceutical compositions
|
JP3648864B2
(ja)
|
1996-08-28 |
2005-05-18 |
三菱自動車工業株式会社 |
希薄燃焼内燃機関
|
DE19651551C2
(de)
*
|
1996-12-11 |
2000-02-03 |
Klinge Co Chem Pharm Fab |
Opioidantagonisthaltige galenische Formulierung
|
US20010036469A1
(en)
|
1997-01-13 |
2001-11-01 |
Gooberman Lance L. |
Opiate antagonist implant and process for preparation therefor
|
US6884879B1
(en)
*
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
GB9801231D0
(en)
*
|
1997-06-05 |
1998-03-18 |
Merck & Co Inc |
A method of treating cancer
|
HU9701081D0
(en)
*
|
1997-06-23 |
1997-08-28 |
Gene Research Lab Inc N |
Pharmaceutical composition of antitumoral activity
|
US6525038B1
(en)
*
|
1997-06-24 |
2003-02-25 |
Werner Kreutz |
Synergistic compositions for the selective control of tumor tissue
|
US6353004B1
(en)
*
|
1997-07-14 |
2002-03-05 |
Adolor Coporation |
Peripherally acting anti-pruritic opiates
|
US6096764A
(en)
|
1997-08-21 |
2000-08-01 |
Eli Lilly And Company |
Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
|
US6559158B1
(en)
*
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
US6274591B1
(en)
*
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
US5972954A
(en)
|
1997-11-03 |
1999-10-26 |
Arch Development Corporation |
Use of methylnaltrexone and related compounds
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
US6777534B1
(en)
|
1997-12-09 |
2004-08-17 |
Children's Medical Center Corporation |
Peptide antagonists of vascular endothelial growth factor
|
NZ505193A
(en)
*
|
1997-12-22 |
2003-03-28 |
Euro Celtique S |
Opioid agonist/antagonist combinations
|
EP0930334A1
(en)
|
1998-01-16 |
1999-07-21 |
Quest International B.V. |
Polysaccharide conjugate capable of binding cellulose
|
JP4470321B2
(ja)
*
|
1998-04-03 |
2010-06-02 |
味の素株式会社 |
抗腫瘍剤
|
US6359111B1
(en)
*
|
1998-05-28 |
2002-03-19 |
Neorx Corporation |
Opioid receptor targeting
|
HN1999000149A
(es)
*
|
1998-09-09 |
2000-01-12 |
Pfizer Prod Inc |
Derivados de 4,4-biarilpiperidina
|
US20010010919A1
(en)
|
1998-10-13 |
2001-08-02 |
David K. Grandy |
Opioid antagonists and methods of their use
|
US6194382B1
(en)
*
|
1999-03-03 |
2001-02-27 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
|
JP4049477B2
(ja)
|
1999-03-23 |
2008-02-20 |
大鵬薬品工業株式会社 |
副作用軽減剤
|
US7129265B2
(en)
|
1999-04-23 |
2006-10-31 |
Mason R Preston |
Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
|
US6171620B1
(en)
*
|
1999-04-27 |
2001-01-09 |
Health Research, Inc. |
Method of enhancing the efficacy of anti-tumor agents
|
AU4564200A
(en)
|
1999-04-29 |
2000-11-17 |
Aventis Pharma S.A. |
Method for treating cancer using camptothecin derivatives and 5-fluorouracil
|
US6765010B2
(en)
*
|
1999-05-06 |
2004-07-20 |
Pain Therapeutics, Inc. |
Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
|
US6833349B2
(en)
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
US20020068712A1
(en)
*
|
1999-07-23 |
2002-06-06 |
Troy Stevens |
Use of decreasing levels of functional transient receptor potential gene product
|
US20030105121A1
(en)
*
|
1999-07-27 |
2003-06-05 |
Bernard Bihari |
Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
|
CA2380524A1
(en)
|
1999-08-25 |
2001-03-01 |
Barrett R. Cooper |
Compositions and methods for treating opiate intolerance
|
US6451806B2
(en)
|
1999-09-29 |
2002-09-17 |
Adolor Corporation |
Methods and compositions involving opioids and antagonists thereof
|
ATE275402T1
(de)
|
1999-11-01 |
2004-09-15 |
John Rhodes |
Arzneimittel zur behandlung von darmverstopfung und reizkolon
|
ATE306281T1
(de)
*
|
1999-11-04 |
2005-10-15 |
Roussy Inst Gustave |
Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
|
US6469030B2
(en)
|
1999-11-29 |
2002-10-22 |
Adolor Corporation |
Methods for the treatment and prevention of ileus
|
WO2001041705A2
(en)
|
1999-11-29 |
2001-06-14 |
Adolor Corporation |
Novel methods for the treatment and prevention of dizziness and pruritus
|
EP1244447B1
(en)
|
1999-11-29 |
2007-01-10 |
Adolor Corporation |
Novel methods and compositions involving opioids and antagonists thereof
|
US6384044B1
(en)
*
|
1999-11-29 |
2002-05-07 |
Bernard Bihari |
Method of treating cancer of the prostate
|
IL149650A0
(en)
|
1999-11-29 |
2002-11-10 |
Adolor Corp |
Novel methods for the treatment and prevention of ileus
|
US6545010B2
(en)
|
2000-03-17 |
2003-04-08 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
|
US20010046968A1
(en)
|
2000-03-23 |
2001-11-29 |
Zagon Ian S. |
Opioid growth factor modulates angiogenesis
|
US6967075B2
(en)
*
|
2000-04-07 |
2005-11-22 |
Schering Corporation |
HCV replicase complexes
|
CN1630532A
(zh)
|
2000-04-19 |
2005-06-22 |
约翰斯霍普金斯大学 |
预防和治疗胃肠疾病的方法
|
CA2408106A1
(en)
|
2000-05-05 |
2001-11-15 |
Pain Therapeutics, Inc. |
Opioid antagonist compositions and dosage forms
|
JP2003535907A
(ja)
*
|
2000-06-22 |
2003-12-02 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
|
EP1175905A1
(en)
|
2000-07-24 |
2002-01-30 |
Societe Des Produits Nestle S.A. |
Nutritional Composition
|
ME00671B
(me)
*
|
2000-07-28 |
2011-12-20 |
Hoffmann La Roche |
Nova farmaceutska smeša
|
US6414016B1
(en)
|
2000-09-05 |
2002-07-02 |
Sucampo, A.G. |
Anti-constipation composition
|
WO2002060870A2
(en)
|
2000-11-17 |
2002-08-08 |
Adolor Corporation |
Delta agonist analgesics
|
AU2002219707A1
(en)
|
2000-12-04 |
2002-06-18 |
Primagen B.V. |
Testing endosymbiont cellular organelles and compounds identifiable therewith
|
AU2002239384B2
(en)
|
2000-12-13 |
2007-01-11 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
US6693125B2
(en)
*
|
2001-01-24 |
2004-02-17 |
Combinatorx Incorporated |
Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
|
US20020172712A1
(en)
|
2001-03-19 |
2002-11-21 |
Alan Drizen |
Antiemetic, anti-motion sustained release drug delivery system
|
HUP0400314A3
(en)
|
2001-03-23 |
2006-02-28 |
Shire Biochem Inc Laval |
Pharmaceutical combinations for the treatment of cancer
|
EP1379274A4
(en)
|
2001-03-23 |
2006-02-15 |
Univ Texas |
METHODS FOR INHIBITING ANGIOGENESIS, TUMOR GROWTH AND METASTASIS USING ANTI-HUMAN ANTI-IL8 AND ANTI-MUC18 IN VARIOUS TYPES OF TUMORS
|
US20040242523A1
(en)
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
NZ528994A
(en)
*
|
2001-04-26 |
2006-02-24 |
Control Delivery Sys Inc |
Sustained release drug delivery system containing codrugs
|
TWI302100B
(en)
*
|
2001-05-02 |
2008-10-21 |
Sucampo Ag |
Composition for treating drug-induced constipation
|
EP1404323B1
(en)
*
|
2001-06-05 |
2009-10-28 |
The University of Chicago |
Use of methylnaltrexone to treat immune suppression
|
WO2003030912A1
(en)
*
|
2001-08-31 |
2003-04-17 |
Sucampo Ag |
Prostaglandin analogs as chloride channel opener
|
WO2003020296A1
(en)
*
|
2001-08-31 |
2003-03-13 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
INHIBITION OF ANGIOGENESIS AND DESTRUCTION OF ANGIOGENIC VESSELS WITH EXTRACTS OF NONI JUICE $i(MORINDA CITRIFOLIA)
|
JP4814488B2
(ja)
|
2001-10-18 |
2011-11-16 |
ネクター セラピューティックス |
重合体共役物オピオイドアンタゴニスト
|
US20030144312A1
(en)
*
|
2001-10-30 |
2003-07-31 |
Schoenhard Grant L. |
Inhibitors of ABC drug transporters in multidrug resistant cancer cells
|
WO2003037365A1
(en)
*
|
2001-11-01 |
2003-05-08 |
The Johns Hopkins University |
Methods and compositions for treating vascular leak using hepatocyte growth factor
|
TWI331920B
(en)
*
|
2001-11-14 |
2010-10-21 |
Sucampo Ag |
Unit dosage form for relieving or treating constipation in human patients
|
TWI263505B
(en)
|
2001-11-19 |
2006-10-11 |
Sucampo Ag |
Pharmaceutical composition comprising a C1C-2 channel opener
|
EP1458710A4
(en)
*
|
2001-12-21 |
2005-04-20 |
Merck & Co Inc |
HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5
|
WO2004014291A2
(en)
|
2002-02-04 |
2004-02-19 |
Jonathan Moss |
Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
|
US20050011468A1
(en)
*
|
2002-02-04 |
2005-01-20 |
Jonathan Moss |
Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
|
IL148244A0
(en)
|
2002-02-19 |
2002-09-12 |
Yissum Res Dev Co |
Anti-nausea and anti-vomiting activity of cannabidiol compounds
|
US7074825B2
(en)
*
|
2002-03-07 |
2006-07-11 |
Huanbiao Mo |
Composition and method for treating cancer
|
US20030191147A1
(en)
|
2002-04-09 |
2003-10-09 |
Barry Sherman |
Opioid antagonist compositions and dosage forms
|
US7355081B2
(en)
|
2002-04-17 |
2008-04-08 |
The University Of North Carolina At Chapel Hill |
Curcumin analogues and uses thereof
|
ATE510553T1
(de)
*
|
2002-05-17 |
2011-06-15 |
Univ Texas |
Beta-2-glycoprotein 1 als angiogenesehemmer
|
US7012100B1
(en)
*
|
2002-06-04 |
2006-03-14 |
Avolix Pharmaceuticals, Inc. |
Cell migration inhibiting compositions and methods and compositions for treating cancer
|
BR0311814A
(pt)
|
2002-06-05 |
2005-03-15 |
Cedars Sinai Medical Center |
Método de tratar câncer empregando inibidores de cinase
|
WO2004007503A1
(ja)
|
2002-07-11 |
2004-01-22 |
Toray Industries, Inc. |
悪心・嘔吐の治療または予防剤
|
US7160913B2
(en)
*
|
2002-09-13 |
2007-01-09 |
Thomas Jefferson University |
Methods and kit for treating Parkinson's disease
|
US7691374B2
(en)
*
|
2002-10-23 |
2010-04-06 |
Health Research, Inc. |
Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
|
EP1562953B1
(en)
|
2002-11-08 |
2009-09-30 |
Mallinckrodt Inc. |
Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
|
WO2004054569A1
(en)
*
|
2002-12-16 |
2004-07-01 |
Council Of Scientific And Industrial Research |
Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
|
US20060281682A1
(en)
|
2003-01-28 |
2006-12-14 |
Currie Mark G |
Methods and compositions for the treatment of gastrointestinal disorders
|
AU2004207009A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Dynogen Pharmaceuticals, Inc. |
Use of sodium channel modulators for treating gastrointestinal tract disorders
|
AU2004220113A1
(en)
*
|
2003-03-07 |
2004-09-23 |
Eli Lilly And Company |
Opioid receptor antagonists
|
ES2527870T5
(es)
|
2003-04-08 |
2022-10-14 |
Progenics Pharm Inc |
Formulaciones farmacéuticas que contienen metilnaltrexona
|
US20040259899A1
(en)
|
2003-04-08 |
2004-12-23 |
Sanghvi Suketu P. |
Combination therapy for constipation
|
BRPI0409128A
(pt)
|
2003-04-08 |
2006-03-28 |
Progenics Pharm Inc |
uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
|
JP4343948B2
(ja)
*
|
2003-04-29 |
2009-10-14 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
体重減少に影響を及ぼすための組成物
|
US6992193B2
(en)
|
2003-06-10 |
2006-01-31 |
Adolor Corporation |
Sulfonylamino phenylacetamide derivatives and methods of their use
|
US7494979B2
(en)
*
|
2003-06-13 |
2009-02-24 |
Ironwood Pharmaceuticals, Inc. |
Method for treating congestive heart failure and other disorders
|
PL1644021T3
(pl)
*
|
2003-06-13 |
2013-01-31 |
Ironwood Pharmaceuticals Inc |
Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
|
AU2003903387A0
(en)
*
|
2003-07-02 |
2003-07-17 |
Sirtex Medical Limited |
Combination therapy for treatment of neoplasia
|
WO2005041759A2
(en)
*
|
2003-10-29 |
2005-05-12 |
Allez Physionix Ltd. |
Method and apparatus for determining an ultrasound fluid flow centerline
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
WO2005087208A2
(en)
*
|
2004-03-10 |
2005-09-22 |
Trustees Of Tufts College |
Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
|
TW200533339A
(en)
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
US6946556B1
(en)
|
2004-05-21 |
2005-09-20 |
Acura Pharmaceuticals, Inc. |
Preparation of opioid analgesics by a one-pot process
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
US7388008B2
(en)
*
|
2004-08-02 |
2008-06-17 |
Ambrilia Biopharma Inc. |
Lysine based compounds
|
US20060063792A1
(en)
*
|
2004-09-17 |
2006-03-23 |
Adolor Corporation |
Substituted morphinans and methods of their use
|
EP2301963A1
(en)
|
2004-09-23 |
2011-03-30 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
JP2008528497A
(ja)
|
2005-01-20 |
2008-07-31 |
プロジェニックス ファーマシューティカルズ,インコーポレーテッド |
メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
WO2006096626A2
(en)
|
2005-03-07 |
2006-09-14 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
AR057035A1
(es)
*
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
CA2609985A1
(en)
|
2005-06-03 |
2007-05-10 |
The University Of Chicago |
Modulation of cell barrier dysfunction
|
AU2006255274A1
(en)
|
2005-06-03 |
2006-12-14 |
The University Of Chicago |
Modulation of microbial pathogen-host cell interactions
|
US20080194611A1
(en)
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
EP1906951A4
(en)
*
|
2005-07-01 |
2009-05-27 |
Dynogen Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR TREATING HYPOMOTILITY OF THE DIGESTIVE SYSTEM AND RELATED DISORDERS
|
PE20070207A1
(es)
*
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
WO2007022531A2
(en)
|
2005-08-19 |
2007-02-22 |
Microbia, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP2009506080A
(ja)
*
|
2005-08-30 |
2009-02-12 |
クィーンズ ユニバーシティー アット キングストン |
超低用量のα−2−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および/またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法
|
WO2007055806A1
(en)
*
|
2005-10-31 |
2007-05-18 |
Indevus Pharmaceuticals, Inc. |
Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
|
US20070259939A1
(en)
|
2006-05-04 |
2007-11-08 |
Accelerated Technologies |
Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
|
JP5905198B2
(ja)
|
2007-10-01 |
2016-04-20 |
ザ ユニヴァーシティー オヴ シカゴ |
薬剤誘発性吐き気のオピオイド拮抗薬による治療
|
WO2009076195A1
(en)
|
2007-12-05 |
2009-06-18 |
The University Of Chicago |
Treatment of drug-induced nausea with opioid antagonists
|
AU2009214500B2
(en)
|
2008-02-14 |
2014-10-23 |
Alkermes, Inc. |
Selective opioid compounds
|